贝康医疗公告,其自主研发PGT-A试剂盒医疗器械注册证获国家药监局批准续期至2030年2月,助力公司股价今日盘中大涨9.38%。
PGT-A试剂盒是国内首个经逾10万例临床样本验证临床有效性的PGT检测试剂盒,能够精准检测胚胎是否存在染色体异常,为医生提供判断胚胎适合植入的重要依据。此次注册证获续期,体现了药监部门对该产品临床有效性的认可。
市场分析人士指出,该试剂盒填补了国内PGT检测试剂盒领域的临床空白,获批续期反映了公司在辅助生殖基因检测解决方案领域的技术实力和市场竞争力。加之今日公司获资金净流入约114万港元,一定程度助推了股价上扬。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.